BiVictriX Therapeutics PLC BiVictriX identifies lead for BVX001 programme (8267I)
December 07 2022 - 2:00AM
UK Regulatory
TIDMBVX
RNS Number : 8267I
BiVictriX Therapeutics PLC
07 December 2022
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company" or the "Group")
BiVictriX identifies development lead for BVX001 programme
Lead identified for the BVX001 programme which demonstrates
encouraging potency and enhanced cancer selectivity
Lead will now be progressed to in vivo studies to obtain
readouts on preclinical efficacy and safety
Alderley Park, 7 December 2022 - BiVictriX Therapeutics plc
(AIM: BVX), an emerging biotechnology company applying a novel
approach to develop next generation cancer therapies using insights
derived from frontline clinical experience, announces that it has
identified a development lead for its BVX001 programme (the
"Lead").
The Lead was developed using BiVictriX's proprietary Bi-Cygni(R)
approach, which aims to generate the next-generation of Antibody
Drug Conjugates ("ADCs") with superior cancer selectivity. The Lead
was selected based on promising in vitro potency and cancer cell
selectivity data, together with encouraging data reported from a
panel of ex-vivo safety assays using healthy human cells.
The Lead, together with backup candidates, will now be taken
forward into a panel of in vivo models. These will include models
of Acute Myeloid Leukaemia to investigate the optimum dose of the
molecule. In addition, the Lead will be assessed in safety models
providing indicative safety data for the programme. Results from
these experiments, in addition to the data already obtained, will
support manufacturing preparations and guide future clinical
trials.
Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics
plc, commented: "We are delighted to be able to announce that we
have identified a lead compound for our BVX001 programme, in line
with what we set out to do earlier this year. This marks a
significant step forward towards progressing this programme to the
clinic, where we hope to deliver key outcomes for patients who
currently have limited options. This announcement also comes at a
time when interest in the ADC sector is on the rise with over 12
deals/partnerships announced this year alone. I would like to thank
the team at BiVictriX for all their hard work in achieving this
fundamental milestone. "
For more information, please contact:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Iain Ross, Chairman Email: info@bivictrix.com
SP Angel Corporate Finance LLP Tel: +44 (0) 20 3470 0470
(NOMAD and Broker)
David Hignell, Kasia Brzozowska
(Corporate Finance)
Vadim Alexandre, Rob Rees (Sales
and Broking)
Panmure Gordon (UK) Limited (Joint Tel: +44 (0) 20 7886 2500
Broker)
Rupert Dearden, Freddy Crossley,
Emma Earl
Consilium Strategic Communications
Mary-Jane Elliott, Namrata Taak, Tel: +44 (0) 20 3709 5700
Genevieve Wilson, Alex Gunter Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company
which is focused on leveraging clinical experience to develop a new
class of highly selective, next generation cancer therapeutics
which exhibit superior potency, whilst significantly reducing
treatment-related harmful side effects.
The Company utilises a first-in-class approach to generate a
proprietary pipeline of Bi-Cygni(R) therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "twin
antigens fingerprints", on tumour cells, which are largely absent
from healthy cells. Whereas this concept has been validated in a
clinical diagnostic setting to support the diagnosis and monitoring
of haematological cancers, it has not yet been widely used in a
therapeutic setting, where it offers the opportunity to be a
game-changing approach to cancer care.
BiVictriX has identified a diverse panel of novel
cancer-specific "twin antigens fingerprints" across a broad range
of cancer indications. The Company is using these novel twin
antigens to develop more effective and safer therapeutics to target
cancers that are expected to constitute orphan indications and
areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDGBDDIGGDGDL
(END) Dow Jones Newswires
December 07, 2022 02:00 ET (07:00 GMT)
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Apr 2024 to May 2024
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From May 2023 to May 2024